Pleomorphic adenoma (PA) is the most common benign salivary gland tumor. Kallikrein-related peptidases have been identified as biomarkers in many human tumors and may influence tumor behavior. We investigated KLK1−15 messenger ribonucleic acid and proteins in PA specimens to determine a KLK expression profile for this tumor. Fresh frozen PA tissue specimens (n = 26) and matched controls were subjected to quantitative real-time reverse transcription polymerase chain reaction to detect KLK1−15 mRNA. Expression of KLK1, KLK12, KLK13, and KLK8 proteins were then evaluated via immunostaining techniques. Statistical analyses were performed with the level of significance set at P < .05. We observed downregulation of KLK1, KLK12, and KLK13 mRNA expression, and immunostaining studies revealed downregulation of the corresponding proteins. Histologic evidence of capsular perforation was associated with increased KLK1 protein expression. Tumor size was not associated with capsular invasion and/or perforation. This study is the first to detail a KLK expression profile for PA at both the transcriptional level and the protein level. Future work is required to develop clinical applications of these findings.
Introduction
Pleomorphic adenoma (PA), also known as benign mixed tumor, is the most common salivary gland neoplasm in all age groups [1] . This tumor accounts for approximately 60-70% of all salivary gland neoplasms, is most common in adults between the ages of 30 and 60, has a slight female predilection, and has a high recurrence rate; however, with adequate surgery, a cure rate of more than 95% is achievable [2, 3] . PA arises in the parotid gland in about 80% of cases, particularly in the tail and inferior aspect of the gland; other locations include the submandibular gland (~ 10%), minor salivary glands (~ 10%), and the sublingual gland (0.3-1%). Surgical treatment of PA by superficial parotidectomy results in decreased recurrence rates compared to simple enucleation of the tumor [1] . Malignant transformation to carcinoma ex-pleomorphic adenoma occurs in 5-10% of cases, making carcinoma ex-PA the fourth most common malignant salivary gland tumor. Cytogenetic analysis has shown translocations in pleomorphic adenoma gene 1 (PLAG1) located at chromosome region 8q12 in approximately 70% of PAs [3] . Recurrent translocations involving the high-mobility group AT-hook 2 (HMGA2) gene are also present in a subset of PAs and carcinoma ex-PAs [4] . Finally, a variety of kallikrein-related peptidase genes (KLKs) have been linked to salivary gland tumors, including PA [5] [6] [7] .
Kallikrein-1 (KLK1) and the remaining kallikrein-related peptidases (KLK2−15) are a family of 15 homologous secreted serine endopeptidases [5] [6] [7] . KLKs are involved in a wide range of normal physiological processes, such as skin desquamation, semen liquefaction, enamel formation, and regulation of the immune response [6, 8, 9] . Studies have also revealed that dysregulation of KLK expression, activity, or localization is frequently associated with pathological disorders, such as respiratory diseases, skin diseases, perturbation of tooth enamel formation, neurological disorders, and carcinogenesis [10] [11] [12] [13] . KLKs control the growth of cancer cells by regulating the bioactivity of several hormones and growth factors through cell surface receptor activation [11] . Furthermore, KLKs promote cancer cell migration and invasion due to their proteolytic action on the extracellular matrix (ECM) [14] . Due to this functional role of KLKs in cancer progression, researchers have studied their utility as therapeutic targets [8, 15] and as biomarkers for disease [16] [17] [18] .
KLKs may be exploited as biomarkers for tumor diagnosis and postoperative monitoring in the management of salivary gland neoplasms [19] [20] [21] . Salivary gland tumors comprise 0.5% of all malignancies and 2-5% of all head and neck malignancies worldwide [22] [23] [24] . Due to the relatively low incidence rates of salivary gland tumors, it is possible that the impact of these neoplasms is misrepresented. To date, the upregulation of KLKs in malignant tumors has been associated with both favorable and poor prognoses [25] . The potential for certain members of the KLK family to guide differential diagnoses, subtyping, and monitoring of patients with salivary gland tumors has been a driving force for research in this field.
The determination of a KLK mRNA and protein expression profile for PA may help to establish a link between KLK dysregulation and the pathophysiology of this tumor. Research groups have analyzed a variety of salivary gland neoplasms to determine relative KLK protein expression compared to normal salivary gland tissue (NSGT) controls [26] [27] [28] [29] [30] [31] [32] [33] ; such neoplasms include PA, adenoid cystic carcinoma (AdCC), acinic cell carcinoma (ACC), polymorphous low-grade adenocarcinoma (PLGA), mucoepidermoid carcinoma (MEC), and adenocarcinoma not otherwise specified (ANOS). In developing a KLK profile for PA, we hope to further our understanding of the roles of KLKs in PA tumorigenesis; furthermore, these findings may facilitate the development of clinical applications for guiding the differential diagnosis, prognosis, and postoperative monitoring of this salivary gland neoplasm.
The aims of this study were to (i) quantitate and compare the expression levels of KLK1−15 mRNA in PA specimens and NSGT controls using quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR); (ii) to analyze protein expression for dysregulated KLKs (determined in [i]) via immunostaining techniques; (iii) to identify associations between histologic evidence of capsular violation (i.e., invasion and/or perforation) and the expression of KLK mRNA and proteins in PA specimens; (iv) to identify associations between histologic evidence of capsular violation and PA tumor size; and (v) to investigate associations between KLK expression and PA recurrence and/or malignant transformation. This is the first report to characterize a KLK profile for PA at both the mRNA and protein level.
Methods
Approval for this case-control study was granted by the University of Western Ontario Health Sciences Research Ethics Board for research involving human subjects. Tissue 1 3 specimens were obtained from 26 (n = 26) subjects who underwent surgical treatment for PA between November, 2007, and December, 2008, at the Department of Otolaryngology-Head & Neck Surgery, London Health Sciences Centre, London, Ontario, Canada. Diagnosis of the lesion was based on criteria determined from the World Health Organization classification of tumors [34] . Normal salivary gland tissue lying outside the tumor capsule was also harvested from each site, which allowed each subject to serve as his/her own control. After surgical resection, both the PA specimens and control tissues were immediately snap-frozen in liquid nitrogen for storage in a freezer cooled to − 80 °C.
The sole selection criterion was confirmation of diagnosis (PA or NSGT) by histologic examination. Patient ages ranged from 19 to 84 years with a mean of 48 years, and the female-to-male ratio was approximately 2:1 (Table 1) . Tumor specimens were retrieved from parotid gland (21 subjects, 81%) and submandibular gland (5 subjects, 19%) tissues. It should be noted that only 17 of the original 26 samples provided sufficient RNA yield for subsequent analyses. The modified age range for usable cases was 20-84 years with a mean of 53 years, and the female-to-male ratio was 11:6. Sixteen tumors were in parotid gland (16 subjects, 94%) and 1 tumor was in submandibular gland (1 subject, 6%) tissue.
RT-qPCR
Specimens were retrieved from the freezer and allowed to warm to room temperature (20−25 °C). A 100-mg piece of tissue was added to a 1.5-mL sterile centrifuge tube and combined with 1-mL of TRIzol Reagent (Thermo Fisher Scientific, Carlsbad, CA, USA, Catalog number: 15596026) for RNA isolation. The solution was homogenized using a homogenizer. The lysate was centrifuged (12,000×g) for 5 min at 4-10 °C, then the supernatant was transferred to a new tube. The solution was incubated for 5 min to permit complete dissociation of the nucleoproteins complex. Next, 0.2 mL of chloroform was added to the tube and the tube cap was closed. This solution was incubated for 2-3 min. The sample was then centrifuged (12,000×g) for 15 min at 4 °C. The mixture separated into three layers: a lower red phenol-chloroform phase, an interphase, and a colorless upper aqueous phase. The upper aqueous phase containing the RNA was transferred to a new tube using a pipette. A solution of 70% ethanol was combined in a centrifuge tube with the RNA solution in a 1:1 ratio (400-µL of each solution was used). The mixture was then hand-mixed. The Aurum Total RNA mini kit (Bio-Rad Laboratories, Hercules, CA, USA, Catalog number: 7326820) was next assembled and utilized according to protocol. Measurements of RNA quantities were then performed using the Qubit RNA BR Assay Kit (Thermo Fisher Scientific, Carlsbad, CA, USA, Catalog number: Q10210).
Subsequent experiments involved reverse transcription of isolated RNA into complementary DNA (cDNA) using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA, Catalog number: 1708890). Next, RTqPCR reactions were carried out using the CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). Each custom PCR plate accommodated six specimens and came loaded with KLK1−15 and β-actin primer assays from the supplier (Qiagen, Germantown, MD, USA). Polymerase chain reaction mixtures consisted of the following: 10-µL of SsoFast EvaGreen Supermix (Bio-Rad Laboratories, Hercules, CA, USA, Catalog number: 1725201), 2-µL of primer assay (KLK + β-actin), 1-µL of previously synthesized KLK cDNA, and 7-µL of nuclease-free water. It should be noted that the SsoFast EvaGreen Supermix contained dNTPs, magnesium chloride, Sso7d-fusion polymerase, EvaGreen dye and stabilizers. A 20-µL volume of the reaction mixture was transferred by pipette to the appropriate well on a PCR plate. The RT-qPCR protocol involved one cycle of 10 min at 95 °C for enzyme activation, followed by 40 cycles of 15 s at 95 °C for denaturation and 40 cycles of 1 min at 60 °C for annealing/extension. The specificity of each PCR amplification was verified by post-RT-qPCR melting curve analysis.
Relative quantitation of RT-qPCR data was performed using the comparative C T (ΔΔC T ) method. The threshold cycle (C T ) of each KLK (i.e., KLK1−15) in PA or control specimens was normalized to the corresponding C T of the housekeeping gene, β-actin, to yield a ΔC T value. Subsequent calculations for mean ΔC T , standard deviation, ΔΔC T , mean ΔΔC T , and standard error of the mean (SEM) values were performed using GraphPad Prism, Version 7.0c for Mac OS X (GraphPad Software, CA, USA). The paired ΔC T values were subjected to Wilcoxon signed-rank test with the level of significance set at P < .05. 
Immunohistochemistry
For immunohistochemistry (IHC) experiments, each of the 26 PA specimens and matched NSGTs were fixed in formalin and embedded in paraffin to facilitate histologic slide preparation according to known techniques [35] . The antibodies used in this study were chosen based on the results of our RT-qPCR analyses. For PA specimens having KLK ∆C T values that were significantly greater or lesser than the values for matched control tissues, the corresponding KLK antibodies were used: KLK1 (Bioss, MA, USA, Catalog number: BS-1963R), KLK12 (Novus Biologicals, CO, USA, Catalog number: NB200-137), KLK13 (Abcam, ON, Canada, Catalog number: AB113227), and KLK8 (Abgent, CA, USA, Catalog number: genta-AP6327B). While the ∆C T value for KLK8 in all PA samples was not significantly different from ∆C T value for control tissues, the KLK8 antibody was used as a reference in the immunostaining experiments. Evaluation of KLK1, KLK12, KLK13, and KLK8 expression in PA and matched NSGT specimens was performed using standard immunostaining techniques. Positive control tissues (i.e., skin or prostate gland) known to express each respective KLK were used to demonstrate a positive staining reaction and to guide preparation of KLK antibody titers [17, 19, 30, [36] [37] [38] [39] [40] . IHC procedures performed on tissues with primary antibody omitted served as negative controls. Both the negative and positive controls were batch controls, not "on-slide" controls. Using the calculated dilution of 1/1000 for the KLK1 polyclonal antibody, PA and NSGT specimens were subjected to the immunostaining protocol. The calculated dilutions of 1/100, 1/2000, and 1/200 were used for the KLK12, KLK13, and KLK8 polyclonal antibodies, respectively. It should be noted that PA specimens used for immunostaining did not show a statistically significant alteration in KLK8 expression relative to NSGT. The intention was to compare staining immunoreactivity scores for the dysregulated KLKs (i.e., KLK1, KLK12, and KLK13) with those for a non-dysregulated KLK (i.e., KLK8).
To prepare the slides for immunostaining, they were first deparaffinized then hydrated through xylenes and a graded ethanol series. The following protocol was then followed for the KLK1, KLK12, KLK13, and KLK8 experiments:
Antigen retrieval was performed using citrate buffer (at pH 6.0) in a decloaking chamber at 125 °C for the KLK12 and KLK13 antigens; for the KLK1 and KLK8 antigens, ethylenediaminetetraacetic acid (EDTA) buffer (at pH 9.0) was used. After antigen retrieval, slides were rinsed and blocked using 10% horse serum. Incubation with the KLK-specific primary antibody was performed using the appropriate dilution, temperature, and time frame. After allowing antibodies to bind antigens overnight, excess antibody was removed by rinsing with phosphate-buffered saline (PBS). Slides were then treated with the secondary antibody (ImmPRESSTM HRP Anti-Rabbit IgG [Peroxidase] Polymer Detection Kit, Vector Laboratories, CA, USA, Catalog number: MP-7401) and incubated at room temperature for 30 min. After rinsing with PBS, a 3,3′-diaminobenzidine (DAB) solution (Vector Laboratories, CA, USA, Catalog number: SK-4100) was applied to the slides for 6-8 min. Deactivation of the DAB solution was achieved by rinsing the slides with water for 5 min. Counterstaining was performed with haematoxylin. Dehydration was achieved by transferring slides through a graded ethanol series followed by a soak in xylenes. Coverslips were applied to the slides using Cytoseal Mounting Medium (VWR, ON, Canada, Catalog number: 48212154). Immunostaining in PA and NSGT specimens is shown for KLK1 (Fig. 1a, b) , KLK12 (Fig. 1c, d ), KLK13 (Fig. 2a, b) , and KLK8 (Fig. 2c, d) .
A semi-quantitative analysis of the immunostained slides was performed under light microscopy according to previously described techniques [31, 32] . The proportion score represented the estimated fraction of positively staining tumor cells (where 0 = none; 1 < 1/100; 2 = (1/100)-(1/10); 3 = (1/10)-(1/ 3); 4 = (1/3)-(2/3); and 5 > 2/3). For staining intensity, the score was represented by the estimated average intensity of staining for tumor cells (where 0 = none; 1 = weak; 2 = intermediate; and 3 = strong). The overall amount of positive staining was then expressed as the sum of the proportion and intensity scores, known as the Overall Staining Score (OSS; ranges: 0 for negative staining, and 2-8 for positive staining). In tumor tissue, cells lining ductlike structures and non-ductal cells were scored for extent of positive staining and staining intensity. For the purposes of this study, duct-like cells were regarded as cells that lined the lumina of duct-like structures within tumor tissues, while non-ductal cells were any tumor cells that were not obviously lining ducts. The staining was assessed by two trained examiners, with comparison and correlation of assessments to produce consistency and to reduce inter-examiner variability. Statistical calculations were performed using GraphPad Prism, Version 7.0c for Mac OS X (GraphPad Software, CA, USA). The level of significance was set at P < .05. Dot plots were prepared to display OSS values for each KLKspecific antibody (Figs. 3, 4, 5, 6 ).
Assessment of Capsular Invasion and/or Perforation
To assess the capsular violation phenomena in tumor tissues, the original histology slides used for diagnosing PA in cases 1-26 were analyzed for evidence of capsular invasion and/ or perforation. Capsular invasion was defined as penetration of PA tumor cells into-but not completely through-the fibrous tumor capsule. Capsular perforation was defined as penetration of PA tumor cells completely through the fibrous tumor capsule into the surrounding normal tissues. Representative slides were chosen to demonstrate each type 1 3 of capsular violation (Fig. 7a-d) . A thick, intact capsule was found for the PA in Fig. 7a . Invasion of tumor into the fibrous capsule was shown for the PA in Fig. 7b . Perforation of tumor through the capsule was identified for the PA in Fig. 7c . Lastly, a positive tumor margin was shown for the PA in Fig. 7d . Statistical analysis was performed to determine associations between capsular violation (i.e., invasion and/or perforation) and KLK mRNA and/or proteins. Statistical calculations were carried out using GraphPad Prism, Version 7.0c for Mac OS X (GraphPad Software, CA, USA) and the level of significance was set at P < .05. A Mann-Whitney U test was performed to compare mean mRNA values (based on ΔΔC T calculations) for KLK1, KLK12, and KLK13 in the various PA cases (Table 2) . Likewise, a Mann-Whitney U test was employed for comparison of the OSS values for ductal cells and non-ductal cells in the various PA cases showing capsular violation (Table 3) .
Tumor Size
Surgical pathology reports for cases 1-26 were examined to obtain measurements of gross tumor specimens such that associations with capsular violation could be determined (Table 4 ). The level of significance for all statistical tests was set at P < .05.
Results

RT-qPCR
From the original 26 paired PA and NSGT specimens, only 17 pairs (65%) produced sufficient RNA yield for cDNA synthesis and subsequent RT-qPCR analyses (see Table 1 ). All 17 pairs of samples were analyzed and the corresponding ΔC T values for each KLK were recorded. Our RT-qPCR experiments revealed a statistically significant decrease in mRNA expression for KLK1 (P = .0114), KLK12 (P = .0444), and KLK13 (P = .0278) in PA relative to NSGTs. In contrast, there were no statistically significant differences in KLK2−11, KLK14, and KLK15 expression between PA and NSGT specimens (P > .05). 
Immunohistochemistry
Staining immunoreactivity scores (i.e., OSS) were calculated for all PA and NSGT specimens treated with KLK1, KLK12, KLK13, or KLK8 polyclonal antibodies (see Figs. 1, 2) . Table 2 Fig. 6 ). Based on the immunostaining analyses, it was evident that median OSS values for PA specimens were greater in ductal cells than in non-ductal cells, which was consistent with previous observations in the literature [26, 28, 31] . No stromal staining was observed for any of the PA specimens. Overall, the statistically significant, albeit small, differences in OSS values for the dysregulated KLKs in PA and NSGT specimens support the findings established at the mRNA level.
Capsular Invasion and/or Perforation
There were no statistically significant differences in the mRNA levels of KLK1 (P = .2345), KLK12 (P = .0830), and KLK13 (P = .5737) in PA specimens with different capsular violation phenomena (i.e., invasion and/or perforation) (Table 3 ). There were also no statistically significant differences in median OSS values for KLK12 [P (ductal cells) = .3170, P (non-ductal cells) = .4094] and KLK13 [P (ductal cells) = .9159, P (non-ductal cells) = .5961] proteins in PA specimens (Table 4) 
Tumor Size
Our investigations demonstrated no statistically significant differences in tumor size between PAs with capsular invasion and/or perforation (P > .05; Table 5 ).
Recurrence and/or Malignant Transformation
Review of the medical records for each subject was performed to determine the number of cases with tumor recurrence and/or malignant transformation. At the 10-year follow-up mark, none of the 26 PA cases had a documented tumor recurrence or malignant transformation. Only one case had a positive tumor margin (see Fig. 7d ), but this case did not present with a recurrence or malignant transformation during the follow-up period. It should be noted that 3 of the 26 cases had died due to unrelated causes during the 10-year postoperative period.
Discussion
To date, our study is the first to identify statistically significant downregulation of KLK1, KLK12, and KLK13 mRNA and proteins in PA specimens. Considering the variety of diseases involving up-and downregulation of KLKs, our findings suggest the involvement of a KLK cascade in the pathophysiology of PA; specifically, the downregulated expression levels of KLK1, KLK12, and KLK13 in PA may account for the low incidence of capsular invasion and/or malignant transformation. The observed downregulation may involve one or more KLK inhibitors, such as SPINK6, which has been shown to inhibit KLK12 and KLK13, but not KLK1 [41] ; however, future work is required to identify such phenomena.
The non-invasive, benign nature of PA could in part be explained by downregulation of KLK1, which is necessary for tumor cell migration, vascular sprouting, and angiogenesis. In normal physiology, KLK1 is most abundantly produced in the pancreas and salivary glands, followed by the colon and the small intestine [36, 38, 40] ; lower concentrations are found in esophagus, kidney, lymph node, prostate, stomach, thyroid, ureter, and vaginal tissues [36] . KLK1 is a key player in the tissue kallikrein-kinin system (KKS)-a system regarded as one of the main mechanisms controlling systemic and local hemodynamics [42] . Studies have implicated this system in the protection from hypertension, vascular remodeling, and renal fibrosis [42, 43] . Kallikrein-1 is constitutively expressed by endothelial cells and it is released upon endothelial cell activation to digest the vascular basement membrane and interstitial matrix [44, 45] . These processes are necessary for migration, vascular sprouting, and angiogenesis. In the presence of decreased KLK1 levels, there may be a reduced rate of vascular basement membrane and interstitial matrix digestion, resulting in slower tumor growth. Decreased KLK12 mRNA and protein expression have been shown to inhibit tumor cell proliferation in AGS gastric cancer cells [46] , and similar processes may occur in PA. KLK12 is highly expressed in a variety of endocrine tissues, including salivary gland and stomach, and dysregulation at the gene and protein levels has been linked to tumorigenesis [36, 46] . One group of investigators evaluated the effects of KLK12 mRNA and protein downregulation on the cell cycle and proliferation of AGS cells-a human gastric adenocarcinoma cell line [46] . The observed KLK12 mRNA and protein expression levels were higher in AGS cells than the GES-1 normal gastric epithelial cells. Transfection of AGS cells with KLK12 small interfering RNA (siRNA) led to downregulation of KLK12 mRNA and protein expression, reduced cell proliferation, and lower cell counts with respect to the negative control. KLK12 siRNA increased the number of AGS cells in G0/G1 and reduced those in S phase of the cell cycle. Moreover, downregulation of KLK12 in AGS cells decreased their ability to penetrate the membrane in a migration assay. Overall, KLK12 siRNA inhibited the proliferation and migration of AGS gastric cancer cells and caused their arrest in the G0/G1 phase of the cell cycle. Similarly, the downregulation of KLK12 in PA may account for the relatively slow rate of tumor growth.
Multiple KLK inhibitors have thus been shown to independently regulate KLK activity and these findings may help to explain the observed downregulation of KLK12 and KLK13 mRNA and proteins in PA. The known sequestration of KLKs by serum protease inhibitors prompted researchers to investigate the interaction of KLK13 with similar inhibitors [47] . Recombinant KLK13 produced in yeast was added to male and female sera and various biological fluids, and the samples were analyzed with a KLK13 enzyme-linked immunosorbent assay (ELISA). Enzymatically active KLK13 was labelled with I-125 and used for in vitro reactions with candidate protease inhibitors and serum samples. The identified inhibitors included α2-antiplasmin, α2-macroglobulin, and α1-antichymotrypsin. Another research group revealed that members of the SPINK family regulate KLK activity through inhibition [48] . These investigators found that SPINK6 exhibited inhibitory activity against KLK12 and KLK13, but not against KLK1, KLK3, and KLK11. Overall, these findings suggest a mechanism for KLK inhibition which could affect KLK expression in PA, but further studies are required to elucidate such processes. KLK13 cleaves the major components of ECM and is believed to be involved in tissue remodeling, and/or tumor invasion and metastasis [49, 50] , which prompted studies of its role in the pathogenesis of salivary gland tumors [30] . A research group recently analyzed the expression levels of KLK13 in benign and malignant salivary gland tumors [31] . Using immunostaining analyses, normal tissues were compared to samples from PA, AdCC, PLGA, ACC, MEC, and ANOS. The results indicated that KLK13 expression was upregulated in most salivary gland tumors. Immunostaining for KLK13 in PA was significantly reduced relative to control samples. Conversely, immunostaining for KLK13 in PLGA, AdCC, and ANOS was significantly increased relative to controls. MEC and ACC did not display much deviation in staining immunoreactivity compared to healthy tissues. When ductal structures were assessed, ductal cells and cells lining duct-like structures revealed more prominent immunostaining intensity than non-ductal cells in most tumors. Overall, these investigators were the first to report downregulation of KLK13 in PA. Our study corroborated these findings for PA and additionally revealed downregulation of KLK13 mRNA compared to control tissues. Such alterations in KLK13 mRNA and proteins may account for the slow rate of growth and benign nature of PA. Downregulation of KLKs in PA may also decrease the invasion and/ or perforation of tumor cells through the fibrous capsule.
Rather than digestion of capsular tissues by KLKs, a more plausible explanation for capsular violation phenomena in PA may be capsular rupture during preoperative fine needle aspiration (FNA) biopsy [51] . This phenomenon, known as capsular pseudoinvasion, has been documented after FNA of follicular adenomas of the thyroid [52] . The lack of differences in mRNA levels for KLK1, KLK12, and KLK13 in PA cases showing capsular invasion and/or perforation supported the assumption that KLKs are not directly responsible for such histological findings. This was reinforced by the decreased expression of KLK12 and KLK13 proteins; however, the increased expression of KLK1 proteins in cases with capsular perforation contradicted this assumption.
Overall, it appears that KLK proteins are not involved in the digestion of capsular tissues to produce capsular invasion and/or perforation, but follow-up experiments are required to clarify such associations.
Consideration of the various PA specimen sizes prompted us to investigate correlations between tumor size and the presence or absence of capsular violation. Since PA may grow to massive proportions over decades, we surmised that larger tumors would not be more likely to demonstrate violation of the fibrous capsule. We observed no significant differences in PA specimen sizes between cases demonstrating capsular invasion and/or perforation, which supported the likelihood that capsular violation phenomena were not caused by digestion of capsular tissues by KLKs. The presence of an intact fibrous capsule allows PA not only to grow as a benign entity for many years, but also facilitates clean surgical dissection around the tumor, which reduces recurrence rates.
There was no documented case of tumor recurrence and/ or malignant transformation for any of the study subjects at the 10-year follow-up mark. This finding was consistent with the decreased recurrence rates for modern surgical treatment of PA (i.e., partial superficial parotidectomy/complete submandibular gland excision vs. simple enucleation) and the low incidence of malignant transformation of this tumor [1] .
Limitations and Future Work
Although it was not the intention of this study to offer final and conclusive solutions, the determination of a KLK profile for PA may help to establish a causative link between KLK dysregulation and the pathophysiology of this tumor. Our case-control study, while restricted by the small number of samples, is foundational work, which warrants further basic mechanistic studies and a large, multi-centered prospective trial.
The nature of the control tissues used were a limitation in this study. Analyzing matched NSGTs from PA-containing glands (i.e., parotid gland or submandibular gland) may have produced KLK mRNA and protein profiles which did not reflect those of healthy salivary gland tissues. Local and systemic host factors that may have contributed to the formation of PA may also have altered the KLK mRNA and protein expression in NSGTs. Moving forward, tissues from healthy salivary glands (e.g., contralateral glands, or glands from healthy controls) should be compared to PA specimens.
The specificity of our IHC staining and the strength of our OSS method were limited by the polyclonal nature of our KLK antibodies and the lack of blinding in the scoring process, respectively. Regarding the KLK-specific primary antibodies, a greater staining specificity may be obtained by using monoclonal antibodies; however, our options were limited to polyclonal antibodies due to the sparse availability of monoclonal antibodies for KLK1, KLK12, KLK13, and KLK8. The OSS method did not involve blinding of the observers to the tissues being examined, which may have introduced observer bias. It should also be noted that the small portions of PA and NSGTs provided by the surgical team did not allow for the preparation of enough histology slides to repeat our IHC experiments. In future studies, monoclonal KLK antibodies should be employed for greater staining specificity, the scoring of immunostaining should be a blinded process, and all immunostaining experiments should be repeated.
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Alternatively, immunofluorescence reactions may be performed to allow for automatic quantification of KLK proteins, which would eliminate observer bias.
Future work may involve the development of a PA cell line, which could be utilized for KLK-specific analyses. Assessment of PA cells subjected to adenoviral delivery of KLK1, KLK12, and KLK13 genes may strengthen the findings of this study if transfected cells demonstrated an increased incidence of invasion and/or malignant transformation. Moreover, identification of KLK1, KLK12, and KLK13 inhibitors in PA may help to explain the observed downregulation of these KLKs. Once KLK expression profiles for other salivary gland neoplasms including MEC, PLGA, AdCC, ACC, ANOS, and carcinoma ex-PA have been determined, a comparison of KLKs in PA and the malignant tumors may be made. If the malignant tumors demonstrated increased levels of KLK1, KLK12, and/or KLK13, it would be interesting to see if the delivery of nanoliposomes containing KLK1-, KLK12-, and KLK13-targeting siRNA would reduce tumor aggressiveness.
In addition to our current study, which analyzed KLK expression in PAs of major salivary glands, we plan to examine KLK expression in PAs of minor salivary gland origin. In doing so, we may develop a better understanding of KLK dysregulation in PAs, and capsular violation phenomena may be more critically examined due to incomplete capsule formation for PAs of minor salivary glands.
One limitation for such a study would be the difficulty in collecting sufficient samples of PAs of minor salivary glands, which occur with much lower frequency than PAs of major salivary glands.
Other investigations may involve the development of multiparametric panels of KLK biomarkers for guiding the differential diagnosis, prognosis, and postoperative monitoring of PA. Gene regions to be investigated by targeted gene sequencing assays may include PLAG1, HMGA2, KLK1, KLK12, and KLK13. The additional information gleaned from KLK-specific IHC staining of FNA samples may improve diagnostic accuracy, which could greatly change the proposed management (e.g., simple enucleation for a benign tumor versus wide local excision for a malignant tumor). This combination of gene level and protein level analyses may facilitate more accurate differential diagnosis of salivary gland tumors, as previous studies have shown pitfalls in relying on immunohistochemistry alone [53] . To rule out distant metastases, serum levels of KLKs should also be investigated in conjunction with a comprehensive physical examination and review of systems. While the development of a simple and convenient serum or saliva test may not be possible for PA due to the downregulation of KLK proteins in this tumor, our foundational work may help to develop such tests for other salivary gland tumors.
Conclusions
To date, our study is the first to identify statistically significant downregulation of KLK1, KLK12, and KLK13 mRNA and proteins in PA by RT-qPCR and IHC analyses, respectively. For PA cases with capsular perforation and invasion, we identified no statistically significant differences in KLK1, KLK12, or KLK13 mRNA expression; however, a statistically significant increase in KLK1 protein was observed in ductal and non-ductal cells of PAs with capsular perforation. We found no significant differences in tumor size for PA cases with capsular violation (i.e., invasion and/or perforation). In the 10-year postoperative period, no PA cases showed any recurrence or malignant transformation. Given the variety of diseases involving up-and downregulation of KLKs, our findings suggest the involvement of a KLK cascade in the pathophysiology of PA; specifically, the decreased expression of KLK1, KLK12, and KLK13 mRNA and proteins in PA may account for the low incidence of capsular invasion and/or malignant transformation. This foundational work may facilitate the development of clinical applications for KLKs in guiding the differential diagnosis, prognosis, and postoperative monitoring of PA. 
